Blood-based MRD testing shows prognostic value beyond 12 months after surgery

▸ TREATMENT

The INTERCEPT prospective study confirms that circulating tumor DNA detection for minimal residual disease predicts recurrence in stage II-IV colorectal cancer patients, with higher recurrence incidence in MRD-positive versus MRD-negative patients even beyond 12 months from surgery. (Gut)